Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 1.00 |
| ▸ | PKLR | P30613 | 1/20 | 0.79 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.79 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.79 |
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | HSD17B3 | P37058 | 3/20 | 0.65 |
| ▸ | ESR1 | P03372 | 5/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.61 |
| ▸ | GLA | P06280 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | MAOA | P21397 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401099 | 1.00 | PDE2A (1.00) | PDE2APKLRNPSR1RXFP1MAPT | |
| SCHEMBL29368885 | 1.00 | PDE2A (1.00) | PDE2APKLRNPSR1RXFP1MAPT | |
| SCHEMBL16663940 | 0.92 | PDE2A (0.85) | PDE2APKLRNPSR1RXFP1MAPT | |
| SCHEMBL29401241 | 0.89 | NPSR1 (1.00) | PDE2APKLRNPSR1RXFP1MAPT | |
| SCHEMBL4420540 | 0.89 | NPSR1 (1.00) | PDE2APKLRNPSR1RXFP1MAPT | |
| SCHEMBL29369247 | 0.89 | NPSR1 (1.00) | PDE2APKLRNPSR1RXFP1MAPT | |
| SCHEMBL15423100 | 0.89 | PKLR (1.00) | PDE2APKLRNPSR1RXFP1MAPT | |
| SCHEMBL29369342 | 0.89 | PKLR (1.00) | PDE2APKLRNPSR1RXFP1MAPT | |
| SCHEMBL15388144 | 0.88 | PDE2A (0.77) | PDE2APKLRNPSR1RXFP1MAPT | |
| SCHEMBL1315246 | 0.88 | PDE2A (0.77) | PDE2APKLRNPSR1RXFP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| CN-114760996-A | Direct AMPK activator compounds in combination with indirect AMPK activator compounds, compositions, methods, and uses thereof | 雀巢产品有限公司 | 2022-07-15 | — | — | CN | claimed |
| US-20220054575-A1 | PROTECTION AGAINST CORONAVIRUS INFECTION BY EXTRACTS AND EXTRACT COMPONENTS | NATREON, INC. (US) | 2022-02-24 | — | — | US | claimed |
| WO-2022040321-A1 | PROTECTION AGAINST CORONAVIRUS INFECTION BY EXTRACTS AND EXTRACT COMPONENTS | NATREON, INC. (US) | 2022-02-24 | — | — | WO | claimed |
| WO-2021105074-A1 | DIRECT AMPK ACTIVATOR COMPOUNDS COMBINED WITH INDIRECT AMPK ACTIVATOR COMPOUNDS, COMPOSITIONS, METHODS AND USES THEREOF | Société des Produits Nestlé S.A. (CH) | 2021-06-03 | — | — | WO | claimed |
| EP-4330245-B1 | N-ALKYL-O-ARYL CARBAMATES OF 6H-DIBENZO[]B,D]PYRAN-3,8-DIOLS AS MITOPHAGY ENHANCERS | Floratek Pharma SA (CH) | 2026-02-04 | — | — | EP | disclosed |
| US-20250381110-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | PROCTER & GAMBLE (US) | 2025-12-18 | — | — | US | disclosed |
| US-12377069-B2 | Compounds, compositions, methods of using, and methods for preparing compounds | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250170224-A1 | METHODS AND COMPOSITIONS FOR TREATING MICROGLIAL DYSFUNCTION AND IMPROVING METABOLIC DYSFUNCTION | ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (DE) | 2025-05-29 | — | — | US | disclosed |
| US-12310943-B2 | Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders | AMAZENTIS SA (CH) | 2025-05-27 | — | — | US | disclosed |
| EP-4555997-A1 | WATER-SOLUBLE COMPOSITION COMPRISING UROLITHIN | Science4Beauty Sp. z o.o. (PL) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025078652-A1 | USE OF A UROLITHIN TO PREVENT/SLOW DOWN HAIR GETTING FINER | L'OREAL (FR) | 2025-04-17 | — | — | WO | disclosed |
| US-20120164243-A1 | Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders | AMAZENTIS SA (CH) | 2012-06-28 | — | — | US | disclosed |
| US-20120069289-A1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120069289-A1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-22 | — | — | US | disclosed |
| WO-2010133278-A1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2010-11-25 | — | — | WO | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12310943-B2 | Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders | NLN, TUFM, TFAM | PDE2A 1530/4885PKLR 1697/4885NPSR1 3498/4885 |
| US-20120164243-A1 | Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders | NLN, TUFM, TFAM | PDE2A 1530/4885PKLR 1697/4885NPSR1 3498/4885 |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | PDE2A 1271/4885PKLR 1194/4885NPSR1 434/4885 |
| US-12377069-B2 | Compounds, compositions, methods of using, and methods for preparing compounds | UTS2R, REN, UMPS | PDE2A 866/4885PKLR 1534/4885NPSR1 2709/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | PDE2A 2205/4885PKLR 2354/4885NPSR1 4550/4885 |
| US-20250381110-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | SQSTM1, BECN1, CUTA | PDE2A 2133/4885PKLR 2787/4885NPSR1 4462/4885 |
| US-20120069289-A1 | LIQUID CRYSTAL DISPLAY | LPXN, VCL, ACP3 | PDE2A 1820/4885PKLR 62/4885NPSR1 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.